Market Lens IQ is a global market intelligence and strategic consulting firm delivering advanced syndicated research reports, customized industry analysis, competitive intelligence, and data-driven advisory solutions to organizations across international markets. With a strong commitment to analytical excellence and innovation, Market Lens IQ empowers enterprises, investors, consultants, and decision-makers with actionable insights that drive strategic growth, operational efficiency, and long-term business transformation in highly competitive industries. The company serves a broad spectrum of industry verticals, including Life Sciences, Consumer Goods, Semiconductor and Electronics, Materials and Chemicals, Construction and Manufacturing, Food and Beverages, Energy and Power, Automotive and Transportation, ICT and Media, Aerospace and Defense, and BFSI (Banking, Financial Services, and Insurance). By combining deep domain expertise with advanced analytics, Market Lens IQ delivers comprehensive market assessments, technology trend analysis, investment intelligence, supply chain insights, pricing analysis, customer behavior studies, and future market forecasts tailored to evolving business requirements.
At the core of Market Lens IQ’s capabilities lies a robust 360-degree research methodology integrating primary research, secondary research, expert interviews, data triangulation, AI- powered analytics, and real-time market monitoring. Our research framework ensures the highest standards of data accuracy, reliability, and strategic relevance by leveraging industry databases, corporate filings, government publications, trade journals, regulatory frameworks, white papers, investor presentations, and global economic indicators. The company specializes in identifying emerging market opportunities, disruptive technologies, innovation ecosystems, competitive benchmarking, regulatory shifts, and high-growth investment segments across global industries. Driven by a client-centric approach, Market Lens IQ collaborates with startups, SMEs, multinational enterprises, private equity firms, institutional investors, and Fortune 500 companies to deliver high-value business intelligence solutions that support informed decision-making and sustainable competitive advantage. Through continuous innovation, digital intelligence capabilities, and industry-focused expertise, Market Lens IQ has established itself as a trusted strategic partner in the global market research and consulting landscape, helping organizations navigate market complexities and capitalize on transformative growth opportunities.
Typhoid Fever Vaccine Market: 7.2% CAGR to 2033?
Typhoid Fever Vaccine Market
Typhoid Fever Vaccine Market: 7.2% CAGR to 2033?
Typhoid Fever Vaccine Market by Vaccine Type (Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine, Others), by Route of Administration (Oral, Injection), by End User (Hospitals and Clinics, Specialty Centers, Others), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific) Forecast 2026-2034
Updated On : Sep 24, 2026|Base Year : 2025|Pages : 0
The global Typhoid Fever Vaccine Market is valued at USD 150.0 million in 2024 and is projected to reach USD 281.0 million by 2033, expanding at a 7.2% CAGR. Demand is concentrated in endemic Asia-Pacific and Africa, where Salmonella Typhi incidence and antimicrobial resistance drive public immunization programs. Conjugate vaccines are the dominant product class, supported by WHO prequalification and Gavi procurement.
Typhoid Fever Vaccine Market Size (In Million)
250.0M
200.0M
150.0M
100.0M
50.0M
0
161.0 M
2025
172.0 M
2026
185.0 M
2027
198.0 M
2028
212.0 M
2029
228.0 M
2030
244.0 M
2031
Analytical momentum comes from three forces: TCV introduction in Gavi-eligible countries, rising travel vaccination requirements, and public tenders replacing older polysaccharide vaccines. The Typhoid Conjugate Vaccine Market is the fastest-growing product category at an estimated 8.5% CAGR, while the Oral Typhoid Vaccine Market and Injectable Typhoid Vaccine Market serve distinct traveler and endemic-use channels.
Asia-Pacific holds an estimated 48% revenue share, driven by India, Indonesia, China, and Pakistan.
Middle East & Africa follows with 22% share, where Gavi and UNICEF purchasing dominates.
North America and Europe together represent 22%, mostly travel and military immunization.
The Pediatric Vaccines Market is the largest end-use volume pool because mass campaigns target children aged 9 months to 15 years.
The Travelers Vaccines Market is smaller by volume but commands higher average prices in private clinics.
Strategic takeaway: suppliers with WHO-prequalified conjugate products and UNICEF long-term arrangements are best positioned. The Bacterial Vaccine Market includes typhoid alongside cholera and shigellosis, creating cross-platform manufacturing synergies. The Vaccine Adjuvant Market and Vaccine Contract Manufacturing Market influence cost structures as demand scales.
Segment Deep-Dive: Conjugate Vaccine Dominance in Typhoid Fever Vaccine Market
Conjugate vaccines generated an estimated 48% of 2024 revenue and are expected to exceed 55% by 2030. They combine Vi polysaccharide with carrier proteins such as CRM197 or tetanus toxoid, producing stronger and longer-lasting immune responses in children under 5. This clinical advantage explains why Gavi and WHO prioritize TCV over older capsular polysaccharide vaccines.
Segment Analysis Matrix
Segment
Growth Rate (CAGR %)
Market Share (%)
Key Demand Driver
Conjugate Vaccine
8.5%
48%
WHO recommendation and Gavi-funded pediatric campaigns
Live Attenuated Vaccine
6.5%
27%
Traveler demand and oral administration preference
Capsular Polysaccharide Vaccine
4.0%
20%
Lower-cost public tenders and adult immunization
Others
5.5%
5%
Research and outbreak response
Sub-Segment Dynamics
Conjugate vaccines are dominated by Bharat Biotech's Typbar-TCV and PT Bio Farma's TCV pipeline. These products require conjugation facilities, increasing capital intensity.
Live attenuated oral vaccines retain a niche in the Travelers Vaccines Market, with PaxVax's Vivotif as a long-standing option. Oral dosing avoids needles but requires cold-chain compliance.
Capsular polysaccharide vaccines remain relevant in price-sensitive national programs, though they are being displaced by TCVs in Gavi-supported countries.
Margin Pressures
Public-sector tender pricing compresses gross margins. A single TCV dose in UNICEF procurement can be below USD 1.50, while private-market travel vaccines may sell for USD 50-100 per course. Manufacturers must offset low tender prices with volume, yield improvements, and the Vaccine Contract Manufacturing Market for fill-finish capacity. The Vaccine Adjuvant Market for carrier proteins and aluminum adjuvants also affects COGS. Cold Chain Logistics Market costs add 5-12% to delivered vaccine prices in low-resource settings.
Typhoid vaccine demand is shaped by epidemiology, immunization policy, and manufacturing economics. The strongest catalysts are Gavi funding, WHO prequalification, and antimicrobial resistance (AMR). Restraints include limited conjugate manufacturing capacity, cold-chain gaps, and uncertain domestic financing after Gavi transition.
Market Dynamics Impact Analysis
Factor Type
Description
Impact Level
Timeline
Driver
WHO 2018 TCV recommendation and Gavi support for mass campaigns
High
Short term
Driver
Rising AMR in Salmonella Typhi, reducing treatment options
High
Long term
Driver
Expansion of childhood immunization budgets in India and Indonesia
Medium
Short-to-medium term
Restraint
Limited global conjugation and fill-finish capacity
High
Short term
Restraint
Cold-chain failures causing 5-15% dose wastage
Medium
Long term
Restraint
Gavi transition and middle-income funding gaps
Medium
Medium term
Quantitative Catalysts
Gavi has supported TCV introduction in more than 15 countries, with eligible cohorts covering tens of millions of children.
India's Universal Immunization Program and Indonesia's national schedules include TCV in high-burden states.
The Oral Typhoid Vaccine Market benefits from travel medicine guidelines in North America and Europe.
Bottlenecks
Conjugate vaccine production requires validated polysaccharide-protein conjugation, raising entry barriers.
Typhoid vaccine demand is tender-driven, creating price ceilings and lumpy order patterns.
The Cold Chain Logistics Market must handle 2-8°C requirements, especially for oral live attenuated products.
The competitive ecosystem includes multinational vaccine developers, emerging-market manufacturers, and specialized travel vaccine suppliers. Public procurement is concentrated among WHO-prequalified suppliers, while private travel clinics support premium pricing.
Vendor Benchmarking Matrix
Company Name
Core Strength
Target Audience
Market Position
Bharat Biotech
WHO-prequalified Typbar-TCV conjugate vaccine
Gavi, UNICEF, national programs
Leader
PT Bio Farma
Large-scale polysaccharide and TCV capacity
Indonesia, UNICEF, regional tenders
Leader
Sanofi
Global vaccine distribution and travel vaccine portfolio
Travel clinics, military, private market
Challenger
PaxVax Inc.
Oral live attenuated typhoid vaccine Vivotif
Travelers, specialty clinics
Niche
China National Biotec Group
Domestic supply and regional export scale
China, Asia-Pacific public buyers
Leader
GlaxoSmithKline
Global vaccine infrastructure and adjuvant expertise
Public and private immunization
Challenger
Scandinavian Biopharma
TCV development and Nordic research networks
Travel and endemic markets
Niche
Prokarium Ltd.
Next-generation oral vaccine platform
Research collaborations
Niche
Bharat Biotech: Typbar-TCV is a WHO-prequalified conjugate vaccine and a key supplier to Gavi-supported countries.
PT Bio Farma: State-owned Indonesian producer with capacity for polysaccharide and conjugate typhoid vaccines.
Sanofi: Leverages global vaccine distribution for travel and endemic-market typhoid products.
PaxVax Inc.: Focuses on the Oral Typhoid Vaccine Market through Vivotif, typically used by travelers.
China National Biotec Group: Dominates domestic Chinese procurement and exports to neighboring markets.
GlaxoSmithKline: Applies vaccine adjuvant and global manufacturing expertise, though its typhoid portfolio is limited.
Scandinavian Biopharma: Develops TCV candidates targeting travelers and endemic populations.
Prokarium Ltd.: Advances oral vaccine platforms that could disrupt injectable delivery.
Strategic Milestones & Recent Developments in Typhoid Fever Vaccine Market
Recent strategic activity centers on capacity expansion, WHO prequalification, and Gavi supply agreements. Manufacturers are investing in conjugate vaccine scale-up and cold-chain partnerships.
Latest Strategic Moves
Date
Company
Event Type
Impact
2023
Bharat Biotech
Capacity expansion
Increased Typbar-TCV supply for UNICEF tenders
2023
PT Bio Farma
Partnership
Advanced TCV development with international partners
2024
Gavi
Procurement
Multi-year TCV supply agreements with multiple manufacturers
2024
Scandinavian Biopharma
Clinical milestone
TCV candidate progressed in traveler and endemic studies
2025
China National Biotec Group
Export expansion
Growth in Asia-Pacific public-sector contracts
2023-2024: Gavi and UNICEF expanded TCV procurement, improving demand visibility for prequalified suppliers.
2024: Bharat Biotech and PT Bio Farma continued capacity investments to meet pediatric campaign volumes.
2024-2025: New entrants focused on oral and thermostable formulations to reduce Cold Chain Logistics Market dependence.
2025: Public tender pricing remained a key competitive lever, with conjugate products gradually displacing polysaccharide vaccines.
Asia-Pacific is the largest and fastest-growing region, followed by Middle East & Africa. North America and Europe are mature, travel-driven markets with higher prices but lower volumes. South America shows moderate growth through public immunization and travel medicine.
Regional Growth Comparison
Region
Projected CAGR (%)
Base Year Valuation
Primary Catalyst
Regulatory Stringency
Asia-Pacific
8.2%
USD 72.0 million
Endemic burden and Gavi-supported TCV campaigns
Moderate to high
Middle East & Africa
7.8%
USD 33.0 million
UNICEF procurement and outbreak response
Moderate
North America
5.5%
USD 18.0 million
Travel vaccination and military requirements
High
Europe
5.0%
USD 15.0 million
Travel medicine and public health guidance
High
South America
6.0%
USD 12.0 million
Urban sanitation gaps and regional tenders
Moderate
Fastest-growing: Asia-Pacific, where India, Indonesia, and Pakistan account for a large share of global typhoid incidence and TCV introductions.
Most mature: North America and Europe, where the Injectable Typhoid Vaccine Market and Oral Typhoid Vaccine Market serve travelers rather than mass pediatric campaigns.
Middle East & Africa: The main growth corridor for Gavi-funded pediatric immunization, though cold-chain and funding gaps persist.
South America: Public tenders and travel clinics support steady demand, with Brazil and Argentina as leading markets.
The Pediatric Vaccines Market remains the volume anchor in Asia-Pacific and Africa, while the Travelers Vaccines Market drives premium pricing in North America and Europe. The Bacterial Vaccine Market benefits from shared manufacturing platforms for enteric vaccines.
Regulatory frameworks determine which typhoid vaccines can enter public tenders. WHO prequalification is the primary gateway for UNICEF and Gavi procurement. In the United States, FDA CBER regulates typhoid vaccines, including Vi polysaccharide and live attenuated products. In Europe, EMA oversees marketing authorizations and pharmacovigilance.
Key policies and standards:
WHO prequalification: Required for UNICEF and Gavi purchases; Bharat Biotech's Typbar-TCV holds this status.
Gavi eligibility: Determines which countries can access subsidized TCV introduction.
FDA and EMA: Enforce good manufacturing practice (GMP), potency assays, and post-market safety reporting.
ISO 9001 and ISO 13485: Quality management standards used by vaccine manufacturers and contract fill-finish sites.
National immunization technical advisory groups (NITAGs): Recommend TCV inclusion based on local burden and cost-effectiveness.
Recent policy shifts include WHO's 2018 TCV position paper, Gavi's 2023-2025 TCV investment case, and expanded AMR action plans. Compliance impacts include higher validation costs, mandatory cold-chain monitoring, and stricter labeling. The Vaccine Contract Manufacturing Market must meet the same GMP standards as brand owners. The Vaccine Adjuvant Market faces additional safety testing for novel carrier proteins.
Supply Chain & Raw Material Dynamics: Typhoid Fever Vaccine Market
Upstream supply depends on Salmonella Typhi strains, Vi polysaccharide purification, carrier proteins, adjuvants, glass vials, and cold-chain equipment. Conjugate vaccine production requires CRM197 or tetanus toxoid as carrier proteins, both with limited supplier bases. Live attenuated vaccines require bacterial seed stocks and lyophilization capacity.
Key material and sourcing dynamics:
Vi polysaccharide: Extracted from Salmonella Typhi Ty2; purification yield affects cost per dose.
Carrier proteins (CRM197, tetanus toxoid): Specialized inputs with few qualified suppliers; price trends upward due to biologics demand.
Adjuvants: Aluminum salts remain common, while newer adjuvants target improved immune response; the Vaccine Adjuvant Market is consolidating.
Glass vials and stoppers: Subject to global biologics demand; vial shortages can delay fill-finish.
Cold-chain equipment: The Cold Chain Logistics Market faces capacity constraints in Africa and South Asia.
Historical disruptions include COVID-19-related vaccine supply chain diversion, which delayed some TCV introductions. Price volatility in carrier proteins and glass vials has been moderate, with 3-7% annual increases for specialized inputs. The Vaccine Contract Manufacturing Market provides surge capacity but adds technology-transfer costs. The Bacterial Vaccine Market benefits from shared fermentation and purification infrastructure, reducing incremental capex for typhoid producers.
Typhoid Fever Vaccine Market Segmentation
1. Vaccine Type
1.1. Live Attenuated Vaccine
1.2. Capsular Polysaccharide Vaccine
1.3. Conjugate Vaccine
1.4. Others
2. Route of Administration
2.1. Oral
2.2. Injection
3. End User
3.1. Hospitals and Clinics
3.2. Specialty Centers
3.3. Others
Typhoid Fever Vaccine Market Segmentation By Geography
1. North America
1.1. United States
1.2. Canada
1.3. Mexico
2. South America
2.1. Brazil
2.2. Argentina
2.3. Rest of South America
3. Europe
3.1. United Kingdom
3.2. Germany
3.3. France
3.4. Italy
3.5. Spain
3.6. Russia
3.7. Benelux
3.8. Nordics
3.9. Rest of Europe
4. Middle East & Africa
4.1. Turkey
4.2. Israel
4.3. GCC
4.4. North Africa
4.5. South Africa
4.6. Rest of Middle East & Africa
5. Asia Pacific
5.1. China
5.2. India
5.3. Japan
5.4. South Korea
5.5. ASEAN
5.6. Oceania
5.7. Rest of Asia Pacific
Typhoid Fever Vaccine Market REPORT HIGHLIGHTS
Aspects
Details
Study Period
2020-2034
Base Year
2025
Estimated Year
2026
Forecast Period
2026-2034
Historical Period
2020-2025
Growth Rate
CAGR of 7.2% from 2020-2034
Segmentation
By Vaccine Type
Live Attenuated Vaccine
Capsular Polysaccharide Vaccine
Conjugate Vaccine
Others
By Route of Administration
Oral
Injection
By End User
Hospitals and Clinics
Specialty Centers
Others
By Geography
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Rest of South America
Europe
United Kingdom
Germany
France
Italy
Spain
Russia
Benelux
Nordics
Rest of Europe
Middle East & Africa
Turkey
Israel
GCC
North Africa
South Africa
Rest of Middle East & Africa
Asia Pacific
China
India
Japan
South Korea
ASEAN
Oceania
Rest of Asia Pacific
Table of Contents
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Objective
1.4. Definitions and Assumptions
2. Executive Summary
2.1. Market Snapshot
3. Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Trends
3.4. Market Opportunity
4. Market Factor Analysis
4.1. Porters Five Forces
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. PESTEL analysis
4.3. BCG Analysis
4.3.1. Stars (High Growth, High Market Share)
4.3.2. Cash Cows (Low Growth, High Market Share)
4.3.3. Question Mark (High Growth, Low Market Share)
4.3.4. Dogs (Low Growth, Low Market Share)
4.4. Ansoff Matrix Analysis
4.5. Supply Chain Analysis
4.6. Regulatory Landscape
4.7. Current Market Potential and Opportunity Assessment (TAM–SAM–SOM Framework)
4.8. MIQ Analyst Note
5. Market Analysis, Insights and Forecast, 2020-2034
5.1. Market Analysis, Insights and Forecast - by Vaccine Type
5.1.1. Live Attenuated Vaccine
5.1.2. Capsular Polysaccharide Vaccine
5.1.3. Conjugate Vaccine
5.1.4. Others
5.2. Market Analysis, Insights and Forecast - by Route of Administration
5.2.1. Oral
5.2.2. Injection
5.3. Market Analysis, Insights and Forecast - by End User
5.3.1. Hospitals and Clinics
5.3.2. Specialty Centers
5.3.3. Others
5.4. Market Analysis, Insights and Forecast - by Region
5.4.1. North America
5.4.2. South America
5.4.3. Europe
5.4.4. Middle East & Africa
5.4.5. Asia Pacific
6. North America Market Analysis, Insights and Forecast, 2020-2034
6.1. Market Analysis, Insights and Forecast - by Vaccine Type
6.1.1. Live Attenuated Vaccine
6.1.2. Capsular Polysaccharide Vaccine
6.1.3. Conjugate Vaccine
6.1.4. Others
6.2. Market Analysis, Insights and Forecast - by Route of Administration
6.2.1. Oral
6.2.2. Injection
6.3. Market Analysis, Insights and Forecast - by End User
6.3.1. Hospitals and Clinics
6.3.2. Specialty Centers
6.3.3. Others
7. South America Market Analysis, Insights and Forecast, 2020-2034
7.1. Market Analysis, Insights and Forecast - by Vaccine Type
7.1.1. Live Attenuated Vaccine
7.1.2. Capsular Polysaccharide Vaccine
7.1.3. Conjugate Vaccine
7.1.4. Others
7.2. Market Analysis, Insights and Forecast - by Route of Administration
7.2.1. Oral
7.2.2. Injection
7.3. Market Analysis, Insights and Forecast - by End User
7.3.1. Hospitals and Clinics
7.3.2. Specialty Centers
7.3.3. Others
8. Europe Market Analysis, Insights and Forecast, 2020-2034
8.1. Market Analysis, Insights and Forecast - by Vaccine Type
8.1.1. Live Attenuated Vaccine
8.1.2. Capsular Polysaccharide Vaccine
8.1.3. Conjugate Vaccine
8.1.4. Others
8.2. Market Analysis, Insights and Forecast - by Route of Administration
8.2.1. Oral
8.2.2. Injection
8.3. Market Analysis, Insights and Forecast - by End User
8.3.1. Hospitals and Clinics
8.3.2. Specialty Centers
8.3.3. Others
9. Middle East & Africa Market Analysis, Insights and Forecast, 2020-2034
9.1. Market Analysis, Insights and Forecast - by Vaccine Type
9.1.1. Live Attenuated Vaccine
9.1.2. Capsular Polysaccharide Vaccine
9.1.3. Conjugate Vaccine
9.1.4. Others
9.2. Market Analysis, Insights and Forecast - by Route of Administration
9.2.1. Oral
9.2.2. Injection
9.3. Market Analysis, Insights and Forecast - by End User
9.3.1. Hospitals and Clinics
9.3.2. Specialty Centers
9.3.3. Others
10. Asia Pacific Market Analysis, Insights and Forecast, 2020-2034
10.1. Market Analysis, Insights and Forecast - by Vaccine Type
10.1.1. Live Attenuated Vaccine
10.1.2. Capsular Polysaccharide Vaccine
10.1.3. Conjugate Vaccine
10.1.4. Others
10.2. Market Analysis, Insights and Forecast - by Route of Administration
10.2.1. Oral
10.2.2. Injection
10.3. Market Analysis, Insights and Forecast - by End User
10.3.1. Hospitals and Clinics
10.3.2. Specialty Centers
10.3.3. Others
11. Competitive Analysis
11.1. Company Profiles
11.1.1. Prokarium Ltd.
11.1.1.1. Company Overview
11.1.1.2. Products
11.1.1.3. Company Financials
11.1.1.4. SWOT Analysis
11.1.2. BIO-MED
11.1.2.1. Company Overview
11.1.2.2. Products
11.1.2.3. Company Financials
11.1.2.4. SWOT Analysis
11.1.3. China National Biotec Group
11.1.3.1. Company Overview
11.1.3.2. Products
11.1.3.3. Company Financials
11.1.3.4. SWOT Analysis
11.1.4. Shanghai institute of biological products co.
11.1.4.1. Company Overview
11.1.4.2. Products
11.1.4.3. Company Financials
11.1.4.4. SWOT Analysis
11.1.5. ltd.
11.1.5.1. Company Overview
11.1.5.2. Products
11.1.5.3. Company Financials
11.1.5.4. SWOT Analysis
11.1.6. GlaxoSmithKline
11.1.6.1. Company Overview
11.1.6.2. Products
11.1.6.3. Company Financials
11.1.6.4. SWOT Analysis
11.1.7. Sanofi
11.1.7.1. Company Overview
11.1.7.2. Products
11.1.7.3. Company Financials
11.1.7.4. SWOT Analysis
11.1.8. PT Bio Farma
11.1.8.1. Company Overview
11.1.8.2. Products
11.1.8.3. Company Financials
11.1.8.4. SWOT Analysis
11.1.9. Paxvax Inc.
11.1.9.1. Company Overview
11.1.9.2. Products
11.1.9.3. Company Financials
11.1.9.4. SWOT Analysis
11.1.10. Scandinavian Biopharma
11.1.10.1. Company Overview
11.1.10.2. Products
11.1.10.3. Company Financials
11.1.10.4. SWOT Analysis
11.1.11. Bharat Biotech
11.1.11.1. Company Overview
11.1.11.2. Products
11.1.11.3. Company Financials
11.1.11.4. SWOT Analysis
11.2. Market Entropy
11.2.1. Company's Key Areas Served
11.2.2. Recent Developments
11.3. Company Market Share Analysis, 2026
11.3.1. Top 5 Companies Market Share Analysis
11.3.2. Top 3 Companies Market Share Analysis
11.4. List of Potential Customers
12. Research Methodology
List of Figures
Figure 1: Typhoid Fever Vaccine Market Revenue Breakdown (million, %) by Region 2026 & 2034
Figure 2: North America Typhoid Fever Vaccine Market Revenue (million), by Vaccine Type 2026 & 2034
Figure 3: North America Typhoid Fever Vaccine Market Revenue Share (%), by Vaccine Type 2026 & 2034
Figure 4: North America Typhoid Fever Vaccine Market Revenue (million), by Route of Administration 2026 & 2034
Figure 5: North America Typhoid Fever Vaccine Market Revenue Share (%), by Route of Administration 2026 & 2034
Figure 6: North America Typhoid Fever Vaccine Market Revenue (million), by End User 2026 & 2034
Figure 7: North America Typhoid Fever Vaccine Market Revenue Share (%), by End User 2026 & 2034
Figure 8: North America Typhoid Fever Vaccine Market Revenue (million), by Country 2026 & 2034
Figure 9: North America Typhoid Fever Vaccine Market Revenue Share (%), by Country 2026 & 2034
Figure 10: South America Typhoid Fever Vaccine Market Revenue (million), by Vaccine Type 2026 & 2034
Figure 11: South America Typhoid Fever Vaccine Market Revenue Share (%), by Vaccine Type 2026 & 2034
Figure 12: South America Typhoid Fever Vaccine Market Revenue (million), by Route of Administration 2026 & 2034
Figure 13: South America Typhoid Fever Vaccine Market Revenue Share (%), by Route of Administration 2026 & 2034
Figure 14: South America Typhoid Fever Vaccine Market Revenue (million), by End User 2026 & 2034
Figure 15: South America Typhoid Fever Vaccine Market Revenue Share (%), by End User 2026 & 2034
Figure 16: South America Typhoid Fever Vaccine Market Revenue (million), by Country 2026 & 2034
Figure 17: South America Typhoid Fever Vaccine Market Revenue Share (%), by Country 2026 & 2034
Figure 18: Europe Typhoid Fever Vaccine Market Revenue (million), by Vaccine Type 2026 & 2034
Figure 19: Europe Typhoid Fever Vaccine Market Revenue Share (%), by Vaccine Type 2026 & 2034
Figure 20: Europe Typhoid Fever Vaccine Market Revenue (million), by Route of Administration 2026 & 2034
Figure 21: Europe Typhoid Fever Vaccine Market Revenue Share (%), by Route of Administration 2026 & 2034
Figure 22: Europe Typhoid Fever Vaccine Market Revenue (million), by End User 2026 & 2034
Figure 23: Europe Typhoid Fever Vaccine Market Revenue Share (%), by End User 2026 & 2034
Figure 24: Europe Typhoid Fever Vaccine Market Revenue (million), by Country 2026 & 2034
Figure 25: Europe Typhoid Fever Vaccine Market Revenue Share (%), by Country 2026 & 2034
Figure 26: Middle East & Africa Typhoid Fever Vaccine Market Revenue (million), by Vaccine Type 2026 & 2034
Figure 27: Middle East & Africa Typhoid Fever Vaccine Market Revenue Share (%), by Vaccine Type 2026 & 2034
Figure 28: Middle East & Africa Typhoid Fever Vaccine Market Revenue (million), by Route of Administration 2026 & 2034
Figure 29: Middle East & Africa Typhoid Fever Vaccine Market Revenue Share (%), by Route of Administration 2026 & 2034
Figure 30: Middle East & Africa Typhoid Fever Vaccine Market Revenue (million), by End User 2026 & 2034
Figure 31: Middle East & Africa Typhoid Fever Vaccine Market Revenue Share (%), by End User 2026 & 2034
Figure 32: Middle East & Africa Typhoid Fever Vaccine Market Revenue (million), by Country 2026 & 2034
Figure 33: Middle East & Africa Typhoid Fever Vaccine Market Revenue Share (%), by Country 2026 & 2034
Figure 34: Asia Pacific Typhoid Fever Vaccine Market Revenue (million), by Vaccine Type 2026 & 2034
Figure 35: Asia Pacific Typhoid Fever Vaccine Market Revenue Share (%), by Vaccine Type 2026 & 2034
Figure 36: Asia Pacific Typhoid Fever Vaccine Market Revenue (million), by Route of Administration 2026 & 2034
Figure 37: Asia Pacific Typhoid Fever Vaccine Market Revenue Share (%), by Route of Administration 2026 & 2034
Figure 38: Asia Pacific Typhoid Fever Vaccine Market Revenue (million), by End User 2026 & 2034
Figure 39: Asia Pacific Typhoid Fever Vaccine Market Revenue Share (%), by End User 2026 & 2034
Figure 40: Asia Pacific Typhoid Fever Vaccine Market Revenue (million), by Country 2026 & 2034
Figure 41: Asia Pacific Typhoid Fever Vaccine Market Revenue Share (%), by Country 2026 & 2034
List of Tables
Table 1: Typhoid Fever Vaccine Market Revenue million Forecast, by Vaccine Type 2020 & 2034
Table 2: Typhoid Fever Vaccine Market Revenue million Forecast, by Route of Administration 2020 & 2034
Table 3: Typhoid Fever Vaccine Market Revenue million Forecast, by End User 2020 & 2034
Table 4: Typhoid Fever Vaccine Market Revenue million Forecast, by Region 2020 & 2034
Table 5: North America Typhoid Fever Vaccine Market Revenue million Forecast, by Vaccine Type 2020 & 2034
Table 6: North America Typhoid Fever Vaccine Market Revenue million Forecast, by Route of Administration 2020 & 2034
Table 7: North America Typhoid Fever Vaccine Market Revenue million Forecast, by End User 2020 & 2034
Table 8: North America Typhoid Fever Vaccine Market Revenue million Forecast, by Country 2020 & 2034
Table 9: United States Typhoid Fever Vaccine Market Revenue (million) Forecast, by Application 2020 & 2034
Table 52: Rest of Asia Pacific Typhoid Fever Vaccine Market Revenue (million) Forecast, by Application 2020 & 2034
Research Methodology & Data Sources
Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.
Primary Research
Primary research accounts for 70-80% of the study, with 20-30% from secondary sources. We conduct structured interviews with vaccine manufacturers, procurement agencies, and immunization program officials.
Target company types include typhoid conjugate vaccine bulk antigen manufacturers, live attenuated oral vaccine fill-finish CDMOs, cold-chain qualified vaccine distributors for endemic regions, government tender procurement agencies, and pediatric and travel vaccine clinic networks.
Stakeholder interviews cover National Immunization Program Procurement Directors, Vaccine Supply Chain Managers, Regulatory Affairs Leads for Biologics, and Pediatric Infectious Disease Specialists.
We validate demand assumptions against real tender awards, WHO prequalification lists, and Gavi investment cases.
Key Stakeholders Interviewed
Stakeholder Role
Interview Share (%)
National Immunization Program Procurement Director
Industry associations and regulatory bodies include the Developing Countries Vaccine Manufacturers Network (DCVMN), WHO Prequalification Team, FDA CBER, and European Medicines Agency (EMA).
Every report is updated to the date of purchase, incorporating the latest tender notices, label changes, and outbreak data.
Demand Modeling & Market Estimation
We use both top-down and bottom-up methodologies simultaneously, validated through multi-level data triangulation.
Top-down modeling starts with global vaccine immunization spending and applies typhoid-specific allocation based on disease burden and product mix.
Bottom-up modeling uses quantitative metrics including number of surviving infants in typhoid-endemic countries, TCV doses administered through Gavi-funded programs, average public-sector tender price per dose, vaccine vial wastage rate in cold chain, and percentage of typhoid cases confirmed by blood culture.
Segment splits are cross-checked against manufacturer capacity, UNICEF supply agreements, and national immunization schedules.
Data Accuracy & Quality Check
We guarantee an estimated data accuracy level of 85-90%, with confidence intervals disclosed for forecast years.
Multi-level data triangulation compares primary interview findings, secondary database extracts, and government tender records.
Outlier screening removes duplicate tender awards and misreported volume data.
Final estimates are reviewed by senior analysts with vaccine market experience before publication.
Frequently Asked Questions
1. Who are the leading companies in the Typhoid Fever Vaccine Market and what does the competitive landscape look like?
Bharat Biotech, PT Bio Farma, Sanofi, PaxVax Inc., and China National Biotec Group are among the most active suppliers. Bharat Biotech's Typbar-TCV is a WHO-prequalified conjugate vaccine that anchors many Gavi-supported immunization programs. The top five vendors are estimated to control roughly 60-70% of global typhoid vaccine supply, while regional producers hold strong positions in public tenders.
2. What are the primary growth drivers and demand catalysts for typhoid vaccines?
Rising antimicrobial resistance in Salmonella Typhi and WHO's 2018 TCV recommendation are core demand catalysts. Gavi has supported TCV introduction in more than 15 countries, with eligible cohorts reaching tens of millions of children. Urbanization, unsafe water, and expanding childhood immunization budgets in Asia-Pacific and Africa add volume. The market is projected to grow at 7.2% CAGR from 2024 to 2033.
3. Which barriers to entry and competitive moats shape the Typhoid Fever Vaccine Market?
WHO prequalification, national regulatory approval, and Gavi tender access create high entry barriers. Conjugate vaccine manufacturing requires polysaccharide-protein conjugation capacity and validated cold-chain release testing. Existing suppliers with prequalified products, such as Bharat Biotech and PT Bio Farma, benefit from multi-year public procurement contracts. Clinical trials for new TCVs can cost USD 20-50 million and take 5-8 years.
4. What major challenges, restraints, or supply-chain risks affect typhoid vaccine supply?
Limited global manufacturing capacity for Vi-conjugate vaccines can cause tender delays, especially when demand spikes. Cold-chain failures in low-resource settings may waste 5-15% of vaccine doses, raising delivered cost. Funding gaps after Gavi transition can slow TCV introductions in middle-income countries. Antimicrobial resistance also increases typhoid treatment costs, but does not directly expand vaccine budgets.
5. How do export-import dynamics and international trade flows influence the typhoid vaccine market?
India and Indonesia are major exporters of typhoid vaccines, with Bharat Biotech and PT Bio Farma supplying UNICEF and Gavi markets. China National Biotec Group serves domestic and regional export demand, while Europe and North America export higher-priced travel vaccines. Tariff-free procurement under UNICEF long-term arrangements shapes trade, and in 2023 UNICEF awarded TCV supply agreements to multiple manufacturers. Import dependence remains high in Africa, where most countries rely on externally funded vaccine purchases.
6. What post-pandemic recovery patterns and long-term structural shifts are visible in typhoid vaccine demand?
Routine immunization catch-up after COVID-19 increased TCV introductions, and Gavi reports that TCV programs have reached more than 50 million children since 2019. Structural shifts include a move from polysaccharide to conjugate vaccines, greater use of oral live attenuated vaccines for travelers, and digital tracking of vaccine stocks. By 2033, conjugate vaccines are expected to hold over 50% of the Typhoid Fever Vaccine Market by product type.
.jpg){kind=small}
